July 26, 2025 04:01 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Jagdeep Dhankar's resignation: Election Commission initiates steps for Vice President elections | Centre bans Ullu, ALTT, other OTT apps over obscene content | Centre bans Ullu, ALTT, other OTT apps over obscene content | Deeply touched by Muizzu's gesture, writes Narendra Modi on X after arriving in Male | Tejashwi Yadav mulls boycotting Bihar polls over SIR, says 'no point in holding elections when people can't vote' | 'EC can't escape': Rahul Gandhi slams poll body for 'cheating' amid uproar over SIR in Bihar | 'Perverse exercise of judicial power': SC slams Karnataka HC bail to actor Darshan in Renukaswamy murder case | Supreme Court stays Bombay HC order acquitting 12 people in Mumbai train bomb blasts case | ED raids Anil Ambani's 35 premises in Delhi and Mumbai for alleged money laundering | PM Modi embarks on visit to the UK and Maldives
Dr Reddy's labs

Dr Reddy's Labs net profit declines 12.6 pc to Rs 579.3 cr in June qtr

| @indiablooms | Jul 29, 2020, at 08:47 pm

Hyderabad/IBNS: Drug manufacturer Dr Reddy's Labs has said its net profit in the June quarter declined 12.60 per cent to Rs 579.3 crore compared with Rs 662.8 crore during the same quarter last month.

The company said its gross margin rose to 56 per cent from 51.7 per cent while its while its revenue from operations rose 15 per cent annually to Rs 4,417.5 crore.

Earnings before interest, taxes, depreciation, and amortization (EBITDA) or operating profit rose 2 per cent to Rs 1,162 crore.

The Hyderabad based company said revenue from India plummeted 10 per cent annually to Rs 630 crore due to lower prescriptions generated and decline in patients visiting clinics and pharmacies.

"The current quarter's financial performance has been strong across all parameter. l am glad that we have been able to serve our patients well and ensured continuity of business operations despite the challenging times. We have started integration and acquired business from Wockhardt and executed two important licencing arrangements for treatment options for COVID-19. Currently, we are working towards bringing both these drugs to multiple markets," G V Prasad, co-chairman and managing director of Dr Reddy's labs  said in a statement

Its revenue from North America, its biggest market, rose 6 per cent to Rs 1730 crore, mainly due to new products and favourable foreign exchange rate, which was offset by price erosion.

"Our operations have continued without much impact. We continued our engagement with doctors through digital channels, ensured regular supplies of our products to meet with the market demand and continued our R&D activities including few projects pertaining to COVID-19," Dr Reddy's Labs said.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm
Close menu